Alberto Santagostino

Author

Centre Hospitalier de Troyes

Also Known As

Alberto Santagostino, Marie C Bene, Marie-Christine Béné

Publications

902

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier de Troyes Assistance Publique – Hôpitaux de Paris Inserm Université d'Angers Centre Hospitalier Universitaire de Grenoble

About

Alberto Santagostino is an author at Centre Hospitalier de Troyes specializing in medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	204
2	Health Sciences	3	3	56
3	Engineering	1	1	117
4	Natural Sciences	1	1	117
5	Public Health	1	1	122

Alberto Santagostino

Publications

841

Citations

H-Index

Page 1

	Year	Citations
Azacitidine for the treatment of patients with acute myeloid leukemia Luca Maurillo, Adriano Venditti, Alessandra Spagnoli, Cancer	2011	144
An Italian national multicenter study for the definition of reference ranges for normal values of peripheral blood lymphocyte subsets in healthy adults. Alberto Santagostino, G Garbaccio, Angela Pistorio, PubMed ImmunologyBlood CellImmunophenotypingImmunotherapyLaboratory Hematology	1999	122
Creating Space for Large Secondary Alcohols by Rational Redesign of <i>Candida antarctica</i> Lipase B Anders O. Magnusson, Johanna C. Rotticci‐Mulder, Alberto Santagostino, ChemBioChem Substrate SelectivityEngineeringRational RedesignMolecular BiologyLarge Secondary Alcohols	2005	117
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study Alessandra Larocca, Vittorio Montefusco, Sara Bringhen, Blood	2013	87
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial Xavier Leleu, Cyrille Hulin, Jérôme Lambert, Nature Medicine	2024	87
Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study Nicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, Blood	2022	75
The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia clinical results in 46 patients Enrica Morra, Mario Lazzarino, Ercole Brusamolino, Cancer	1993	57
Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study Annalisa Arcari, Annalisa Chiappella, Michele Spina, Leukemia & lymphoma/Leukemia and lymphoma	2015	34
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial François Guilhot, Françoise Rigal‐Huguet, Joëlle Guilhot, Leukemia Hematological MalignancyInterferon Alpha 2AOncologyChronic Myeloid LeukaemiaHematology	2021	27
Atypical Takotsubo syndrome during anagrelide therapy Riccardo Proietti, Andrea Rognoni, Fabio Ardizzone, Journal of Cardiovascular Medicine ThrombosisInverted Takotsubo SyndromeHeart FailureCardiomyopathyCardiovascular Disease	2009	26

Page 1